Hims & Hers HealthHIMS
HIMS
About: Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Employees: 1,046
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
43% more call options, than puts
Call options by funds: $123M | Put options by funds: $85.6M
40% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 7 (+2) [Q3]
35% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 48
4% more funds holding
Funds holding: 291 [Q2] → 302 (+11) [Q3]
9% more repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 91
2.54% less ownership
Funds ownership: 65.65% [Q2] → 63.11% (-2.54%) [Q3]
12% less capital invested
Capital invested by funds: $2.74B [Q2] → $2.42B (-$315M) [Q3]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$18
35%
downside
Avg. target
$29
5%
upside
High target
$42
51%
upside
10 analyst ratings
6 positive
60%
2 neutral
20%
2 negative
20%
Citigroup Daniel Grosslight 39% 1-year accuracy 9 / 23 met price target | 10%downside $25 | Sell Downgraded | 10 Jan 2025 |
BTIG David Larsen 44% 1-year accuracy 8 / 18 met price target | 26%upside $35 | Buy Initiated | 7 Jan 2025 |
Piper Sandler Korinne Wolfmeyer 36% 1-year accuracy 16 / 45 met price target | 14%downside $24 | Neutral Maintained | 6 Jan 2025 |
Needham Ryan MacDonald 56% 1-year accuracy 38 / 68 met price target | 11%upside $31 | Buy Maintained | 6 Jan 2025 |
Morgan Stanley Craig Hettenbach 40% 1-year accuracy 2 / 5 met price target | 51%upside $42 | Overweight Initiated | 17 Dec 2024 |
Financial journalist opinion
Based on 20 articles about HIMS published over the past 30 days
Positive
Seeking Alpha
6 hours ago
Hims & Hers: Ready To Outperform Further
Hims & Hers Health is a rapidly growing telehealth leader with a unique, customer-focused business model, demonstrated by its aggressive customer base expansion and accelerating revenue growth momentum. The company's strong operating leverage, consistent EBITDA margin expansion, and robust free cash flow have built a fortress balance sheet, enabling both organic and inorganic growth opportunities. My intrinsic value per share estimate is significantly higher compared to the current share price.
Positive
MarketBeat
9 hours ago
Hims & Hers Health: A Stock to Trade or Own?
Hims & Hers Health Inc. NYSE: HIMS, a telehealth company with a $6.1 billion valuation, has been a remarkable growth story, especially over the past year. The stock climbed an astounding 215% in 2024, significantly outperforming the broader market and its sector.
Positive
Seeking Alpha
1 day ago
Hims & Hers Health: The Market Is Likely Wrong
Hims & Hers Health is undervalued despite impressive growth, with analysts overly focused on compounded GLP-1s and potential FDA restrictions. BoA's negative outlook contrasts with Hims' projected 90% YoY Q4 growth and strong non-GLP-1 business expansion. Hims' innovative product launches, such as meal replacement bars, highlight its focus on personalized health services and continuous growth potential.
Negative
The Motley Fool
3 days ago
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
A shake-up may be brewing in the market for GLP-1 diet drugs Friday, and it's making itself felt all across the field of companies selling (or hoping to sell) semaglutide and related drugs for treating diabetes and losing weight. As of 11 a.m.
Positive
MarketBeat
3 days ago
Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Positive
The Motley Fool
4 days ago
Is Hims & Hers Stock in Trouble?
Hims & Hers Health (HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth company has been growing at a fast rate, making it one of the best stocks to own in healthcare of late.
Neutral
Zacks Investment Research
6 days ago
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $25.90, moving +1.93% from the previous trading session.
Positive
The Motley Fool
1 week ago
Hims & Hers Stock Is Poised for a Major Surge in 2025
Hims & Hers (HIMS -4.02%) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the stock. But the business is about much more than just one product, and Travis Hoium explains why investors should expect an expanded platform in 2025.
Negative
Seeking Alpha
1 week ago
Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns
Hims & Hers capitalizes on telehealth growth in hair, mental, sexual health, and weight loss. Yet, limited product differentiation, reliance on branding, and FDA risks weaken its long-term moat. Forecasting $3.79B in revenue and $1.08 EPS by 2030, a $45.90 midpoint price target implies an 11.5% five-year CAGR, underperforming a 15% return expectation for a Buy rating. Despite strong branding and subscription revenue, slim competitive advantages and valuation concerns justify a Hold rating, emphasizing risks from generic pricing and market competition.
Positive
Zacks Investment Research
1 week ago
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Charts implemented using Lightweight Charts™